No takes yet. Share an insight, caveat, or question.
Randomized noninferiority trial demonstrates noninferior efficacy of dolutegravir/lamivudine to triple therapy in suppressed HIV, supporting two-drug maintenance in routine clinical practice.
Vasylyev et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: